Cheryl L-L Chiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2607159/publications.pdf

Version: 2024-02-01

28 papers	1,910 citations	471371 17 h-index	677027 22 g-index
29 all docs	29 docs citations	29 times ranked	2646 citing authors

#	Article	IF	Citations
1	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	5.8	326
2	Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity. Journal of Immunology, 2010, 184, 824-835.	0.4	281
3	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	2.1	203
4	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	2.7	201
5	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	3.2	178
6	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2013, 2, e22664.	2.1	154
7	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	1.5	91
8	Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunology, Immunotherapy, 2006, 55, 1384-1395.	2.0	58
9	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	1.8	57
10	Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor. Clinical Cancer Research, 2008, 14, 4898-4907.	3.2	56
11	Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. Frontiers in Immunology, 2019, 10, 2283.	2.2	56
12	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE, 2011, 6, e28732.	1.1	43
13	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine, 2011, 9, 198.	1.8	43
14	In vivo cancer vaccination: Which dendritic cells to target and how?. Cancer Treatment Reviews, 2018, 71, 88-101.	3.4	32
15	Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy, 2015, 15, 569-582.	1.4	30
16	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	2.9	27
17	The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383.	3.4	25
18	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16

#	Article	IF	Citations
19	Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology, 2020, 65, 190-196.	3.3	9
20	Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma. Frontiers in Immunology, 2021, 12, 695150.	2.2	8
21	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines, 2018, 6, 79.	2.1	7
22	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. Cancers, 2021, 13, 4553.	1.7	6
23	Abstract LB-335: Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer.. , 2013, , .		2
24	A phase-I trial of a novel autologous oxidized whole-tumor antigen vaccine therapy for recurrent ovarian cancer. Gynecologic Oncology, 2013, 130, e11-e12.	0.6	0
25	Abstract LB-133: Vaccination with dendritic cells pulsed with autologous oxidized whole tumor lysate induced strong and long-lasting anti-tumor immunity in recurrent ovarian cancer patients. , 2012, , .		0
26	Abstract PR15: Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer.. , 2013, , .		0
27	Abstract IA27: Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials. , 2013, , .		0
28	Tumor lysates cancer vaccine. , 2022, , 21-49.		0